Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Howard Williams who wrote (12206)	7/9/2013 4:35:59 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (2) \| Respond to of 13111

I have stated before that I am quite interested in seeing the Moffitt MOA data...and have been looking for this since 2010. We will wait to see what they find, but I would be stunned if it is a simple yes/no answer with so few patients and likely no placebo control. Overall, I would have been happier if they had done the 15 patient MOA pilot prior to the PII. Had they done this first, they could have captured a potentially robust MOA dataset from the 80 patients, possibly even salvaging the nodal stage III and stage IV subjects....but they have chosen a different path, so we will wait and see what they find.